Skip to main content

Zilretta FDA Approval History

FDA Approved: Yes (First approved October 6, 2017)
Brand name: Zilretta
Generic name: triamcinolone acetonide
Dosage form: Extended-Release Injectable Suspension
Company: Flexion Therapeutics, Inc.
Treatment for: Osteoarthritis

Last updated by Judith Stewart, BPharm on May 20, 2021.

Zilretta (triamcinolone acetonide extended-release injectable suspension) is a corticosteroid intra-articular injection indicated for the management of osteoarthritis pain of the knee.

Add as a preferred source on Google Google preffered source badge

Development timeline for Zilretta

DateArticle
Oct  6, 2017Approval Flexion Therapeutics Announces FDA Approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for Osteoarthritis Knee Pain
Feb  7, 2017Flexion Therapeutics Announces NDA for Zilretta (FX006) Accepted by U.S. FDA
Dec 12, 2016Flexion Therapeutics Submits New Drug Application for Zilretta to Treat Knee Osteoarthritis Pain
May 26, 2016Flexion Therapeutics Receives Positive Guidance from FDA on NDA Submission for Zilretta for Osteoarthritis of the Knee

See also

Zilretta (triamcinolone acetonide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer